Molecular Biosystems' Albunex
Executive Summary
Contrast imaging agent for use with ultrasound is "approvable" at FDA, company announces April 28. The agency's letter asks the firm to make some labeling changes and conduct post-approval studies "relating to the nature and frequency of any reported 'adverse device effects' (ADEs)" as requested by FDA's Radiological Devices Panel in July 1992. MBI says the ADEs that occurred during clinical trials "were both minor and resolved without treatment," and the San Diego-based company will respond to FDA "in the next few days." Albunex will be marketed in the U.S. by Mallinckrodt Medical
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth